Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of acalabrutinib (Calquence) in chronic lymphocytic leukemia and related transformations
2023-509346-35-00Phase 2Authorised
- Sponsor
- Acerta Pharma
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Richter's syndrome (RS), diffuse large B-cell lymphoma (DLBCL) and 1 more, sponsored by Acerta Pharma. Primary endpoints: Overall response rate, Duration of response and 7 more. Planned start Sep 2024; status: authorised.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Richter's syndrome (RS)diffuse large B-cell lymphoma (DLBCL)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on 2023-509346-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509346-35-00.